Drugs.com - FDA MedWatch Alerts

Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal System 25 mcg/h Due to a Defective Delivery System

Audience: Consumer, Health Professional, Pharmacy January 31, 2025 – Morristown, NJ -- Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall...

Feb 9, 2025 - 21:44
 0
Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal System 25 mcg/h Due to a Defective Delivery System
Audience: Consumer, Health Professional, Pharmacy January 31, 2025 – Morristown, NJ -- Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall...
Read More

Tags:

Previous Article

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiov...

Next Article

Provepharm Inc. Issues Recall of One Lot of Phenylephrine Hydrochloride Injectio...

Related Posts

Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause

Drug Safety Communication: FDA Adds Warning About Rare ...

Feb 9, 2025  0

One Source Nutrition, Inc. Issues Voluntary Nationwide Recall of Vitality Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

One Source Nutrition, Inc. Issues Voluntary Nationwide ...

Feb 23, 2025  0

Public Safety Notification on Amniotic Fluid Eyedrops

Public Safety Notification on Amniotic Fluid Eyedrops

Feb 9, 2025  0